284 related articles for article (PubMed ID: 35123676)
1. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954
[TBL] [Abstract][Full Text] [Related]
3. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
[TBL] [Abstract][Full Text] [Related]
4. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
[TBL] [Abstract][Full Text] [Related]
5. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
6. Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA; Janjua M; Chanchlani N; Lin S; Bewshea C; Nice R; McDonald TJ; Auckland C; Harries LW; Davies M; Michell S; Kok KB; Lamb CA; Smith PJ; Hart AL; Pollok RC; Lees CW; Boyton RJ; Altmann DM; Sebastian S; Powell N; Goodhand JR; Ahmad T
Gut; 2023 Feb; 72(2):295-305. PubMed ID: 35902214
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.
Cerna K; Duricova D; Lukas M; Machkova N; Hruba V; Mitrova K; Kubickova K; Kostrejova M; Teplan V; Vasatko M; Kastylova K; Lukas M
Inflamm Bowel Dis; 2022 Oct; 28(10):1506-1512. PubMed ID: 34849919
[TBL] [Abstract][Full Text] [Related]
9. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
10. Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.
Liu Z; Alexander JL; Yee Eng K; Ibraheim H; Anandabaskaran S; Saifuddin A; Constable L; Castro Seoane R; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N
J Crohns Colitis; 2024 Apr; 18(4):560-569. PubMed ID: 37941436
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5-6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis.
Parry H; Bruton R; Tut G; Ali M; Stephens C; Greenwood D; Faustini S; Hughes S; Huissoon A; Meade R; Brown K; Amirthalingam G; Otter A; Hallis B; Richter A; Zuo J; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e554-e560. PubMed ID: 34401865
[TBL] [Abstract][Full Text] [Related]
12. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
13. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S; Kennedy NA; Saifuddin A; Sandoval DM; Reynolds CJ; Seoane RC; Kottoor SH; Pieper FP; Lin KM; Butler DK; Chanchlani N; Nice R; Chee D; Bewshea C; Janjua M; McDonald TJ; Sebastian S; Alexander JL; Constable L; Lee JC; Murray CD; Hart AL; Irving PM; Jones GR; Kok KB; Lamb CA; Lees CW; Altmann DM; Boyton RJ; Goodhand JR; Powell N; Ahmad T;
Nat Commun; 2022 Mar; 13(1):1379. PubMed ID: 35296643
[TBL] [Abstract][Full Text] [Related]
14. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
15. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
16. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
[TBL] [Abstract][Full Text] [Related]
17. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
[TBL] [Abstract][Full Text] [Related]
18. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
[No Abstract] [Full Text] [Related]
19. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
20. Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.
Otten AT; Bourgonje AR; Horinga PP; van der Meulen HH; Festen EAM; van Dullemen HM; Weersma RK; van Leer-Buter CC; Dijkstra G; Visschedijk MC
Front Immunol; 2022; 13():920333. PubMed ID: 35865529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
